Drugs in Dev. Ophthalmology
IND Enabling
China 
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DF-003 is a highly potent first-in-class, oral investigational inhibitor of ALPK1 and the ALPK1 T237M driver mutation that causes disease in ROSAH syndrome patients.
Product Name : DF-003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HG004
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HG004 injection is a new ophthalmic gene therapy drug designed to treat RPE65 gene mutation-related retinopathy. It has successfully obtained the IND approval from the US FDA
Product Name : HG004
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : HG004
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SKG0106
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SKG0106 is a proprietary novel recombinant adeno-associated viral vector containing a uniquely configured transgene with potent inhibition effect on intraocular neovascularization, that is being developed for the treatment of serious ophthalmic condition...
Product Name : SKG0106
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : SKG0106
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFS-02
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON
Details : Investigational NFS-02, a novel recombinant adeno-associated viral serotype 2 vector (rAAV2) containing a codon-optimized of NADH-dehydrogenase subunit 1 gene, is a novel ophthalmic injection that is being developed for the treatment of Leber hereditary ...
Product Name : NFS-02
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : NFS-02
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFS-01
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INDA Clearance received from USFDA for NFS-01 (NR082), a novel recombinant adeno-associated viral serotype 2 on the basis of results from three investigator-initiated trials which demonstrated favorable results in patients LHON associated ND4 mutation.
Product Name : NFS-01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 18, 2022
Lead Product(s) : NFS-01
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFS-01
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : CMG-SDIC Capital
Deal Size : $60.0 million
Deal Type : Series C Financing
Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies
Details : The financing will be used to progress its lead clinical program in LHON to ex-China, enrich R&D pipeline and programs through business development and continue to expand the international standard gene therapy manufacturing platform.
Product Name : NFS-01
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 22, 2021
Lead Product(s) : NFS-01
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : CMG-SDIC Capital
Deal Size : $60.0 million
Deal Type : Series C Financing
Lead Product(s) : NFS-01
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy
Details : NR082, a novel recombinant adeno-associated viral serotype 2 containing a codon-optimized of ND4 gene under the control of the cytomegalovirus promoter and enhancer, is a novel ophthalmic injection that is being developed for the treatment of LHON in ND4...
Product Name : NFS-01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 04, 2021
Lead Product(s) : NFS-01
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Morgan Stanley
Deal Size : Undisclosed
Deal Type : Public Offering
Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange
Details : Ocumension's IPO marks a significant milestone in its journey to become China's leading ophthalmology platform. Company intent to use these funds to continue expanding its portfolio with innovative new drug assets.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Morgan Stanley
Deal Size : Undisclosed
Deal Type : Public Offering
Reset All
